[
  {
    "ts": "2026-02-20T07:00:00+00:00",
    "headline": "U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA速 (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)",
    "summary": "AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA速 (venetoclax) and acalabrutinib for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL). The approval is supported by data from the Phase 3 AMPLIFY trial.1",
    "url": "https://finance.yahoo.com/news/u-food-drug-administration-fda-070000361.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "dbec8ad6-6a0a-3b71-98b4-e19c0df9e3cc",
      "content": {
        "id": "dbec8ad6-6a0a-3b71-98b4-e19c0df9e3cc",
        "contentType": "STORY",
        "title": "U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA速 (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)",
        "description": "",
        "summary": "AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA速 (venetoclax) and acalabrutinib for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL). The approval is supported by data from the Phase 3 AMPLIFY trial.1",
        "pubDate": "2026-02-20T07:00:00Z",
        "displayTime": "2026-02-20T07:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/41f69f15bd3bc61c4f58a58b4cb0aef6",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_lYBdZ6deIjyT9JEkTbBlQ--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/41f69f15bd3bc61c4f58a58b4cb0aef6.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lbpa0nBqHlbEGEv5DWOrMQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/41f69f15bd3bc61c4f58a58b4cb0aef6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/u-food-drug-administration-fda-070000361.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/u-food-drug-administration-fda-070000361.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-20T10:12:00+00:00",
    "headline": "Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading",
    "summary": "Key market opportunities in the fill finish manufacturing sector include rising demand for cell and gene therapies, expansion in personalized medicine production, and increased outsourcing to CMOs. Growth is driven by innovations in aseptic filling technologies, automated systems, and a focus on regulatory compliance. Fill Finish Manufacturing Market Fill Finish Manufacturing Market Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The \"Fill Finish Manufacturing Market Report 2026\" has been added to Res",
    "url": "https://finance.yahoo.com/news/fill-finish-manufacturing-market-analysis-101200216.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "530fa36f-23f9-3c36-930e-b1e0bd755d3a",
      "content": {
        "id": "530fa36f-23f9-3c36-930e-b1e0bd755d3a",
        "contentType": "STORY",
        "title": "Fill Finish Manufacturing Market Analysis Report 2026-2035: A $21+ Billion Market by 2030 with Johnson & Johnson, AbbVie, Thermo Fisher Scientific, BD & Co, Baxter, Lonza, and Catalent Leading",
        "description": "",
        "summary": "Key market opportunities in the fill finish manufacturing sector include rising demand for cell and gene therapies, expansion in personalized medicine production, and increased outsourcing to CMOs. Growth is driven by innovations in aseptic filling technologies, automated systems, and a focus on regulatory compliance. Fill Finish Manufacturing Market Fill Finish Manufacturing Market Dublin, Feb. 20, 2026 (GLOBE NEWSWIRE) -- The \"Fill Finish Manufacturing Market Report 2026\" has been added to Res",
        "pubDate": "2026-02-20T10:12:00Z",
        "displayTime": "2026-02-20T10:12:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/c201a6b6162c9ca9558b3d0f6e4bfd73",
          "originalWidth": 600,
          "originalHeight": 400,
          "caption": "Fill Finish Manufacturing Market",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YEFkB.3vg6z.ia.EasevXw--~B/aD00MDA7dz02MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c201a6b6162c9ca9558b3d0f6e4bfd73.cf.webp",
              "width": 600,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gOcn1xFpIW6M.YNyetyDVQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c201a6b6162c9ca9558b3d0f6e4bfd73.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/fill-finish-manufacturing-market-analysis-101200216.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/fill-finish-manufacturing-market-analysis-101200216.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "TMO"
            },
            {
              "symbol": "BDX"
            },
            {
              "symbol": "BAX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-20T13:08:23+00:00",
    "headline": "Barclays launches U.S. biopharma coverage with four preferred picks",
    "summary": "Investing.com -- Barclays launched coverage of U.S. large-cap biopharmaceutical companies, arguing the sector could regain investor attention in an uncertain macro backdrop, while naming Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY) and AbbVie Inc (NYSE:ABBV) as its top picks.",
    "url": "https://finance.yahoo.com/news/barclays-launches-u-biopharma-coverage-130823921.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "5ba041e7-1a78-33cf-944e-d7c09e3eea86",
      "content": {
        "id": "5ba041e7-1a78-33cf-944e-d7c09e3eea86",
        "contentType": "STORY",
        "title": "Barclays launches U.S. biopharma coverage with four preferred picks",
        "description": "",
        "summary": "Investing.com -- Barclays launched coverage of U.S. large-cap biopharmaceutical companies, arguing the sector could regain investor attention in an uncertain macro backdrop, while naming Eli Lilly (NYSE:LLY), Merck (NYSE:MRK), Bristol-Myers Squibb (NYSE:BMY) and AbbVie Inc (NYSE:ABBV) as its top picks.",
        "pubDate": "2026-02-20T13:08:23Z",
        "displayTime": "2026-02-20T13:08:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/barclays-launches-u-biopharma-coverage-130823921.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/barclays-launches-u-biopharma-coverage-130823921.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-20T13:16:00+00:00",
    "headline": "Will Immunology Drugs Continue to Drive AbbVie's Top Line in 2026?",
    "summary": "ABBV's Skyrizi and Rinvoq drove more than 40% growth in 2025. Can these immunology blockbusters power double-digit gains again in 2026?",
    "url": "https://finance.yahoo.com/news/immunology-drugs-continue-drive-abbvies-131600312.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "24e301b3-d582-323f-9d1b-371db6f67c44",
      "content": {
        "id": "24e301b3-d582-323f-9d1b-371db6f67c44",
        "contentType": "STORY",
        "title": "Will Immunology Drugs Continue to Drive AbbVie's Top Line in 2026?",
        "description": "",
        "summary": "ABBV's Skyrizi and Rinvoq drove more than 40% growth in 2025. Can these immunology blockbusters power double-digit gains again in 2026?",
        "pubDate": "2026-02-20T13:16:00Z",
        "displayTime": "2026-02-20T13:16:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TNBAnrhWOnvvvNSvMEIuFg--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/rP7ZEHNft_Sb_FB9M.3i3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/immunology-drugs-continue-drive-abbvies-131600312.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/immunology-drugs-continue-drive-abbvies-131600312.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]